RiskBenefit Perspective Despite theoretical concerns, the clinical reality is clear: GLP-1 therapies produce substantial weight loss Improve glycemic control and cardiometabolic outcomes Reduce cardiovascular risk in multiple studies When evaluating carcinogenicity risk, current evidence suggests: Strong rodent signals exist but may not translate to humans Long-term human data has not confirmed increased thyroid cancer risk Regulatory warnings remain precautionary rather than confirmatory Conclusion The GLP-1 receptor agonist classfrom Liraglutide to next-generation oral agents like Orforglipronrepresents one of the most transformative areas in metabolic medicine
Michael Greger, M.D., FACLM, is a physician, New York Times best-selling author, founder of NutritionFacts.org, and a founding member and Fellow of the American College of Lifestyle Medicine, and internationally recognized speaker on nutrition, food safety, and public health issues
2 References 1 Weiss, Jessica B., et al
Researchers are now exploring whether GLP-1 receptor activation may offer protective effects within the brain
